The addition of the monoclonal antibody interleukin-5 inhibitor mepolizumab to maintenance therapy appears to reduce the rate of exacerbations in patients with eosinophilic phenotype chronic obstructive pulmonary disease (COPD), according to results of the phase III METREX* and METREO** trials presented at ERS 2017.
The human IgG2 monoclonal antibody tezepelumab reduces asthma exacerbations in patients whose disease remained uncontrolled despite treatment with long-acting beta-agonists and inhaled glucocorticoids, a phase II trial has shown.
The anti-eosinophilic monoclonal antibody benralizumab improved annual exacerbation rates (AER) in patients with severe, uncontrolled asthma, with the improvement more pronounced with increasing baseline blood eosinophil levels and a history of more frequent exacerbations, pooled analysis of the phase III SIROCCO* and CALIMA** trials showed.
The dual endothelin-receptor antagonist macitentan shows promise in improving haemodynamics and exercise capacity in patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH), according to results of the phase II MERIT-1* trial presented at ERS 2017.
Switching from bilevel positive airway pressure (BiPAP) to continuous positive airway pressure (CPAP) ventilation therapy may be safe and cost-effective in patients with obesity hypoventilation syndrome and sleep apnoea, a small study presented at the ERS 2017 has shown.
Initiating therapy with fluticasone furoate plus vilanterol resulted in improved asthma control over usual care in individuals with symptomatic asthma, according to results of the Salford Lung Study presented at ERS 2017.
Hormone replacement therapy (HRT) may help delay lung function decline in middle-aged women, according to results of a longitudinal analysis presented at ERS Congress 2017, demonstrating a possible role for female sex hormones in the preservation of lung function.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Doctor - Malaysia digital copy today!
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.